BACKGROUND: In patients with haematological or oncological malignancies, we aimed to assess the rate of intestinal colonisation and blood stream infections (BSI) with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) and vancomycin-resistant enterococci (VRE), mortality and risk factors associated with ESBLE/VRE BSI, as well as the impact of faecal screening for ESBLE and VRE in combination with adapted empiric treatment of febrile neutropenia. METHODS: Within 72 h of admission to our department, an ESBLE and VRE screening stool sample was collected. In the case of neutropenic fever, blood cultures were drawn. Data of all admitted patients were prospectively documented. Explorative forward-stepwise logistic regression analyses were used to identify risk factors for progression from intestinal colonisation to BSI. RESULTS: During the study period, 1,805 stool samples were obtained from 513 patients during 1,012 inpatient stays, and 2,766 blood cultures were obtained from 578 patients during 1,091 inpatient stays. Ninety (17.5 %) of these patients were colonised with ESBLE and 51 (9.9 %) with VRE. Proportions of 40 % (36/90) of ESBLE and 61 % (31/51) of VRE colonisations were healthcare-associated. Six of 90 (6.6 %) ESBLE-colonised patients and 1/51 (2 %) VRE-colonised patients developed BSI with the respective organism. None of these patients died after receiving early appropriate empiric antibiotics based on colonisation status. Colonisation with ESBLE or VRE was associated with increased risk ratios (RR) towards developing ESBLE BSI [RR 4.5, 95 % confidence interval (CI): 2.89-7.04] and VRE BSI (RR 10.2, 95 % CI: 7.87-13.32), respectively. Acute myelogenous leukaemia and prior treatment with platinum analogues or quinolones were identified as independent risk factors for ESBLE BSI in colonised patients. CONCLUSIONS: Intestinal ESBLE/VRE colonisation predicts BSI. Faecal screening in haematology/oncology patients in combination with directed empiric treatment may reduce ESBLE BSI-related mortality.
BACKGROUND: In patients with haematological or oncological malignancies, we aimed to assess the rate of intestinal colonisation and blood stream infections (BSI) with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) and vancomycin-resistant enterococci (VRE), mortality and risk factors associated with ESBLE/VRE BSI, as well as the impact of faecal screening for ESBLE and VRE in combination with adapted empiric treatment of febrile neutropenia. METHODS: Within 72 h of admission to our department, an ESBLE and VRE screening stool sample was collected. In the case of neutropenic fever, blood cultures were drawn. Data of all admitted patients were prospectively documented. Explorative forward-stepwise logistic regression analyses were used to identify risk factors for progression from intestinal colonisation to BSI. RESULTS: During the study period, 1,805 stool samples were obtained from 513 patients during 1,012 inpatient stays, and 2,766 blood cultures were obtained from 578 patients during 1,091 inpatient stays. Ninety (17.5 %) of these patients were colonised with ESBLE and 51 (9.9 %) with VRE. Proportions of 40 % (36/90) of ESBLE and 61 % (31/51) of VRE colonisations were healthcare-associated. Six of 90 (6.6 %) ESBLE-colonised patients and 1/51 (2 %) VRE-colonised patients developed BSI with the respective organism. None of these patients died after receiving early appropriate empiric antibiotics based on colonisation status. Colonisation with ESBLE or VRE was associated with increased risk ratios (RR) towards developing ESBLE BSI [RR 4.5, 95 % confidence interval (CI): 2.89-7.04] and VRE BSI (RR 10.2, 95 % CI: 7.87-13.32), respectively. Acute myelogenous leukaemia and prior treatment with platinum analogues or quinolones were identified as independent risk factors for ESBLE BSI in colonised patients. CONCLUSIONS: Intestinal ESBLE/VRE colonisation predicts BSI. Faecal screening in haematology/oncology patients in combination with directed empiric treatment may reduce ESBLE BSI-related mortality.
Authors: Carles Ubeda; Ying Taur; Robert R Jenq; Michele J Equinda; Tammy Son; Miriam Samstein; Agnes Viale; Nicholas D Socci; Marcel R M van den Brink; Mini Kamboj; Eric G Pamer Journal: J Clin Invest Date: 2010-11-22 Impact factor: 14.808
Authors: Mini Kamboj; Dick Chung; Susan K Seo; Eric G Pamer; Kent A Sepkowitz; Ann A Jakubowski; Genovefa Papanicolaou Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: J J Vehreschild; M J G T Rüping; H Wisplinghoff; F Farowski; A Steinbach; R Sims; A Stollorz; K-A Kreuzer; M Hallek; C Bangard; O A Cornely Journal: J Antimicrob Chemother Date: 2010-04-21 Impact factor: 5.790
Authors: Alexander A Padiglione; Rory Wolfe; Elizabeth A Grabsch; Di Olden; Stephen Pearson; Clare Franklin; Denis Spelman; Barrie Mayall; Paul D R Johnson; M Lindsay Grayson Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191
Authors: Amanda Kosack; Elyn Riedel; Timothy E Kiehn; Trudy N Small; Leonard H Wexler; Ira J Dunkel Journal: Pediatr Blood Cancer Date: 2009-02 Impact factor: 3.838
Authors: Michael J Satlin; Kalyan D Chavda; Thomas M Baker; Liang Chen; Elena Shashkina; Rosemary Soave; Catherine B Small; Samantha E Jacobs; Tsiporah B Shore; Koen van Besien; Lars F Westblade; Audrey N Schuetz; Vance G Fowler; Stephen G Jenkins; Thomas J Walsh; Barry N Kreiswirth Journal: Clin Infect Dis Date: 2018-11-13 Impact factor: 9.079
Authors: Maria J G T Vehreschild; Miriam Haverkamp; Lena M Biehl; Sebastian Lemmen; Gerd Fätkenheuer Journal: Infection Date: 2018-09-03 Impact factor: 3.553
Authors: M Papadimitriou-Olivgeris; E Drougka; F Fligou; F Kolonitsiou; A Liakopoulos; V Dodou; E D Anastassiou; E Petinaki; M Marangos; K S Filos; I Spiliopoulou Journal: Infection Date: 2014-08-21 Impact factor: 3.553
Authors: P R Niumsup; U Tansawai; A Na-Udom; D Jantapalaboon; K Assawatheptawee; A Kiddee; T Romgaew; S Lamlertthon; T R Walsh Journal: Eur J Clin Microbiol Infect Dis Date: 2017-09-16 Impact factor: 3.267
Authors: E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-25 Impact factor: 3.267